Age 63
Position Chairman-designate, Actelion
JP Garnier was never likely to retire quietly after quitting as chief executive of GlaxoSmithKline. His pay deal at the pharmaceuticals giant meant that he never need work again after leaving in 2008 — even though a clause that would have allowed him $36 million if he had been sacked got him into trouble with shareholders.
Yet he appears to be eager to return to the coal face as chairman of Actelion, the Swiss biotech that knows almost as much as he does about shareholder unrest. The embattled biotech has appointed Mr Garnier vice-chairman and plans to make him chairman when the incumbent Robert Cawthorn leaves next year.
Robert Bertolini, former chief financial officer of Schering-Plough, has also been appointed